The medication exists · the emergency exists · the gap is the four minutes between them
A closed-loop wearable that senses, decides, and delivers — when a person is alone, and no one is there to act.
The drug already works. The person already has it nearby. The only thing missing is a hand to deliver it in the four minutes that decide whether they live.
Remote patient monitoring is a roughly $16B industry. It measures heart rate, oxygen, breathing — and when a patient is dying, the intervention is a phone call1. Monitoring without delivery is observation, not rescue. SmartShot is the layer that closes that distance: it does not call for help, it acts.
When the person is alone, the clock runs out
54,045 Americans died of opioid overdose in 2024.2 Most rescues need a conscious bystander who is not there. The failure is not the drug. It is the distance.
One body. Sense, decide, deliver.
A single insulated wearable worn against the skin. The band senses. The reservoir holds the dose at temperature. The cartridge swaps. The port delivers one confirmed dose. Every part exists in shipping medical hardware today — no one has shipped them as one closed loop.
Four conditions. Four medications.
Each target pairs a life-threatening emergency with a proven drug, a detectable biosignal, and a clear regulatory analogue. Opioid overdose is the beachhead because the signal is the most validated and the buyer is the most funded. The others wait for it.
The telemetry is the product. The tiers are the moat.
SmartShot is not meant to be a fully autonomous device. Streaming vitals route every decision to one of four tiers — a 24/7 staffed command center confirms when device confidence falls short. The same data trail is the FDA pathway, the liability frame, and the registry.
The architecture is proven in maintenance care. No one has shipped it for the emergency.
Healthcare technology follows one pattern: observe first, then intervene. CGM preceded closed-loop insulin. Telemetry preceded the implantable defibrillator. The monitoring layer matures, then delivery follows. That second step has not been taken for emergency medication.
Closed-loop insulin
The sense-decide-deliver loop already runs in millions of insulin pumps. The original move is applying it to the emergency — across drugs — under human-supervised tiers.
Pre-prototype. The value is the thesis, not a device.
There is no working unit, no clinical data, and no FDA engagement. What exists is the analysis a serious team would otherwise pay to assemble: the category, the beachhead logic, and the regulatory map.
Remote Medication Delivery
The term RMD is original to SmartShot — the intervention layer above remote monitoring. Named, framed, and positioned as category creation, not a product pitch.
Naloxone, deliberately first
Chosen for the most validated signal, an OTC drug, the most thermally stable cartridge, and a funded buyer — over $50B in opioid settlement dollars flowing to states now.9
Regulatory map & falsification
FDA Class III, combination product, no predicate. Five named barriers — sensor accuracy, drug stability, miniaturization, liability, regulation — each with a stated falsification test.
Start where the buyer is obvious and already funded.
The beachhead picks the buyer. Opioid overdose has a customer that is named and paid for — the harder, higher-acuity conditions follow once the loop validates on the easiest signal.
Harm reduction & states
SAMHSA, state programs, and MAT clinics, drawing on more than $50B in opioid settlement funds flowing now.9 The funded, motivated first buyer.
Correctional & reentry
Post-release overdose risk is acute and concentrated. A bounded population where the wearable’s economics and the duty to act both line up.
Health systems & payers
High-risk discharge and DME pathways, priced against insulin-pump precedent. The recurring-revenue case once the device is cleared.
VA & allergy / cardiac
Veterans, then the anaphylaxis and cardiac conditions — the platform extensions that wait for the beachhead to prove the loop.
One operator’s hand — with the operating record to read the thesis against.
Joe Nalley is Staff Vice President of Carelon Growth (Elevance Health), where he owns six high-acuity clinical risk books — MSK, oncology, CHF, maternity, autoimmune, and dementia — across more than $50B in specialty medical spend.
He built and sold a 13-location integrated health system, and founded and sold ClearBill, a billing-integrity platform that returned $9.2M to payers in its first six months of full deployment.
SmartShot is concept IP, not yet a company. The operating record is why a pre-prototype thesis is worth reading.
The drug exists.
The emergency exists.
The hand does not — yet.
SmartShot is looking for the people who can pressure-test a pre-prototype thesis honestly: clinical, regulatory, and engineering readers who can tell the team where the loop breaks first.
A full brief — canon, beachhead analysis, regulatory pathway, and falsification tests — is available on request.
The brief, on request
- The category thesis: monitoring → delivery (RMD)
- Beachhead economics and the naloxone-first logic
- Four-layer architecture and the four-tier control hub
- FDA pathway research and five falsification tests
Every external number, cited.
- Remote patient monitoring market size, ~$16B (2024 estimates). Grand View Research / Mordor Intelligence, RPM market reports.
- Drug overdose deaths, 54,045 (2024 provisional, illicit-opioid involved). CDC National Center for Health Statistics, Vital Statistics Rapid Release. “Alone” estimate 39–83%: peer-reviewed overdose-witness literature.
- Anaphylaxis time to cardiac arrest (~5–30 min; ~14 min mean for food/venom). Pumphrey RSH, fatal anaphylaxis case series; AAAAI clinical guidance.
- Out-of-hospital cardiac arrest, ~350,000/yr U.S. American Heart Association, Heart Disease & Stroke Statistics.
- Hybrid closed-loop insulin delivery, FDA-cleared systems (Medtronic 780G, Insulet Omnipod 5, Tandem Control-IQ). FDA device clearances; manufacturer labeling.
- Zoll LifeVest wearable cardioverter-defibrillator, FDA-cleared 2001. ZOLL / FDA premarket records.
- Wearable naloxone auto-injector research. University of Washington Medicine / published device research, pre-clinical.
- Anaphylaxis-detection wearable research, “Project Abbie.” Harvard Wyss Institute, research stage.
- Opioid litigation settlements totaling >$50B distributed to states. National opioid settlement administrators; state attorneys-general reporting.
SmartShot